Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1075 Single Rising Dose in HCV
NCT02392494Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of MK-1075 in hepatitis C (HCV) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Experiencing an Adverse Event (AE), Percentage of Participants Who Discontinued Study Due to an AE and 1 more. Started Apr 2015; status: completed.
02
Drugs
MK-1075
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02392494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392494.